Nuo Therapeutics, Inc. SEC filings

Filings

Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.

1. ROUTINE8-KNuo Therapeutics, Inc.AURXOct 8

   Nuo Therapeutics extends funding closing

   • Second Funding of $325,000 closed on Oct 6, 2026
   • Lenders extended closing date from Sep 30 to Oct 6
   • Scott Pittman, a major shareholder, assumed $25,000
2. ROUTINE4Nuo Therapeutics, Inc.AURXOct 8

   Nuo Therapeutics, Inc. (AURX) filed Form 4

   • Reporting person: Pittman Scott M.
   • Date of transaction: 10/06/2026
   • Acquired 4,500 warrants

   Scott M. Pittman, reporting

3. ROUTINE4Nuo Therapeutics, Inc.AURXSep 1

   David Emerson Jorden, insider filing for AURX

   David Emerson Jorden, reporting

4. ROUTINE4/ANuo Therapeutics, Inc.AURXAug 31

   David Emerson Jorden, insider filing for AURX (amended)

   David Emerson Jorden, reporting

5. ROUTINE8-KNuo Therapeutics, Inc.AURXAug 17

   Current report

6. NOTABLE10-QNuo Therapeutics, Inc.AURXAug 14

   Quarterly report

7. ROUTINE4Nuo Therapeutics, Inc.AURXJul 2

   5 insider filings

   Peter Clausen, insider filing for AURX

   Show all 5

   • 4Insider filing for AURXJul 2
   • 4Insider filing for AURXJul 2
   • 4Insider filing for AURXJul 2
   • 4Insider filing for AURXJul 2
   • 4Insider filing for AURXJul 2

   Peter Clausen, reporting

8. ROUTINE4Nuo Therapeutics, Inc.AURXJun 5

   David Emerson Jorden, insider filing for AURX

   David Emerson Jorden, reporting

9. NOTABLESCHEDULE 13D/ANuo Therapeutics, Inc.AURXJun 3

   Ownership stake disclosure by Scott M. Pittman (amended)

   Scott M. Pittman, filed by

10. ROUTINE4Nuo Therapeutics, Inc.AURXJun 2

    2 insider filings

    Scott M. Pittman, insider filing for AURX

    Show all 2

    • 4Insider filing for AURXJun 2
    • 4/AInsider filing for AURX (amended)Jun 2

    Scott M. Pittman, reporting

11. ROUTINE8-KNuo Therapeutics, Inc.AURXMay 14

    Current report

12. NOTABLE10-QNuo Therapeutics, Inc.AURXMay 14

    Quarterly report

13. NOTABLE10-KNuo Therapeutics, Inc.AURXMar 30

    Annual report

14. ROUTINESCHEDULE 13G/ANuo Therapeutics, Inc.AURXFeb 12

    Ownership stake disclosure by Paul Anthony Jacobs (amended)

    Paul Anthony Jacobs, filed by

15. ROUTINE4Nuo Therapeutics, Inc.AURXJan 26

    Scott M. Pittman, insider filing for AURX

    Scott M. Pittman, reporting

16. NOTABLESCHEDULE 13D/ANuo Therapeutics, Inc.AURXJan 26

    Ownership stake disclosure by Scott M. Pittman (amended)

    Scott M. Pittman, filed by

17. ROUTINE8-KNuo Therapeutics, Inc.AURXJan 26

    Current report

18. ROUTINE4Nuo Therapeutics, Inc.AURXJan 5

    David Emerson Jorden, insider filing for AURX

    David Emerson Jorden, reporting

19. ROUTINE4Nuo Therapeutics, Inc.AURXDec 22, 2025

    C Eric Winzer, insider filing for AURX

    C Eric Winzer, reporting

20. ROUTINE8-KNuo Therapeutics, Inc.AURXDec 17, 2025

    Current report

21. ROUTINE4/ANuo Therapeutics, Inc.AURXDec 11, 2025

    Paul Mintz, insider filing for AURX (amended)

    Paul Mintz, reporting

22. ROUTINE4Nuo Therapeutics, Inc.AURXDec 11, 2025

    Paul Mintz, insider filing for AURX

    Paul Mintz, reporting

23. ROUTINE4Nuo Therapeutics, Inc.AURXDec 3, 2025

    David Emerson Jorden, insider filing for AURX

    David Emerson Jorden, reporting

24. NOTABLE10-QNuo Therapeutics, Inc.AURXOct 30, 2025

    Quarterly report

25. ROUTINEDEF 14ANuo Therapeutics, Inc.AURXOct 30, 2025

    Proxy statement

26. ROUTINEDEFA14ANuo Therapeutics, Inc.AURXOct 30, 2025

    Additional proxy materials

Older filings on EDGAR